Research ExplorerPublicationsAn open-label, Phase I study of cediranib (RECENTIN) in pati...

An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.

Standard

An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. / Fiedler, Walter; Mesters, Rolf; Heuser, Michael; Ehninger, Gerhard; Berdel, Wolfgang E; Zirrgiebel, Ute; Robertson, Jane D; Puchalski, Tom A; Collins, Barbara; Jürgensmeier, Juliane M; Serve, Hubert.

In: LEUKEMIA RES, 2009.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Fiedler, W, Mesters, R, Heuser, M, Ehninger, G, Berdel, WE, Zirrgiebel, U, Robertson, JD, Puchalski, TA, Collins, B, Jürgensmeier, JM & Serve, H 2009, 'An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.', LEUKEMIA RES. <http://www.ncbi.nlm.nih.gov/pubmed/19674789?dopt=Citation>

APA

Fiedler, W., Mesters, R., Heuser, M., Ehninger, G., Berdel, W. E., Zirrgiebel, U., Robertson, J. D., Puchalski, T. A., Collins, B., Jürgensmeier, J. M., & Serve, H. (2009). An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. LEUKEMIA RES. http://www.ncbi.nlm.nih.gov/pubmed/19674789?dopt=Citation

Vancouver

Fiedler W, Mesters R, Heuser M, Ehninger G, Berdel WE, Zirrgiebel U et al. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. LEUKEMIA RES. 2009.

Bibtex

@article{d6492e1ae19847498be43c7756dff670,
title = "An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.",
abstract = "VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of",
author = "Walter Fiedler and Rolf Mesters and Michael Heuser and Gerhard Ehninger and Berdel, {Wolfgang E} and Ute Zirrgiebel and Robertson, {Jane D} and Puchalski, {Tom A} and Barbara Collins and J{\"u}rgensmeier, {Juliane M} and Hubert Serve",
year = "2009",
language = "Deutsch",
journal = "LEUKEMIA RES",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.

AU - Fiedler, Walter

AU - Mesters, Rolf

AU - Heuser, Michael

AU - Ehninger, Gerhard

AU - Berdel, Wolfgang E

AU - Zirrgiebel, Ute

AU - Robertson, Jane D

AU - Puchalski, Tom A

AU - Collins, Barbara

AU - Jürgensmeier, Juliane M

AU - Serve, Hubert

PY - 2009

Y1 - 2009

N2 - VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of

AB - VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of

M3 - SCORING: Zeitschriftenaufsatz

JO - LEUKEMIA RES

JF - LEUKEMIA RES

SN - 0145-2126

ER -